Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PCVX
PCVX logo

PCVX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Vaxcyte Inc (PCVX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
57.910
1 Day change
-4.55%
52 Week Range
65.000
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

PCVX is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows a constructive technical uptrend and some supportive sentiment from congress purchases, but the absence of recent news, no strong proprietary buy signal, and options positioning that leans heavily bearish make the setup mixed rather than decisive. Since the user is impatient and does not want to wait for an ideal entry, the best call is to hold off on buying and wait for a stronger confirmation or a better risk-reward entry.

Technical Analysis

PCVX is trading at 58.77 after closing near the prior close, with a modest regular-session gain and slight post-market strength. The trend is bullish on the chart: SMA_5 > SMA_20 > SMA_200, which supports an uptrend. MACD histogram is positive at 1.058 but contracting, suggesting momentum is still positive but cooling. RSI_6 at 74.453 indicates the stock is extended rather than offering an attractive fresh entry. Price is currently near resistance at R1 58.444 and below R2 60.628, with pivot support at 54.908. Overall, trend is bullish but short-term upside may be limited without a pullback or breakout confirmation.

Options Data

Bearish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Options sentiment is cautious-to-bearish. The open interest put-call ratio of 3.03 is very elevated, indicating heavy put positioning versus calls. Option volume put-call ratio of 1.54 also leans bearish. Implied volatility at 51.93 is moderately elevated versus historical volatility of 45.01, while IV rank at 8.79 and IV percentile at 21.43 suggest options are not especially expensive relative to their recent range. The overall options picture points to hedging or downside caution rather than strong bullish conviction.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
8

Positive Catalysts

  • supports the existing uptrend.", "Congress trading shows 2 purchase transactions and 0 sales in the last 90 days, a positive signal.", "Pattern-based stock trend suggests a 70% chance of gains over the next day, week, and month, with estimated upside of 2.35% next day, 4.51% next week, and 10.91% next month.", "Post-market price is still slightly positive, showing no immediate breakdown after the close."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no event-driven catalyst helping the stock now.", "AI Stock Picker has no signal today and SwingMax has no recent signal, so Intellectia proprietary signals do not confirm a strong entry.", "RSI is elevated, suggesting the stock is somewhat stretched after the recent run.", "Options positioning is heavily skewed toward puts, with a 3.03 open interest put-call ratio.", "Hedge funds and insiders are both neutral, offering no strong accumulation signal."]

Financial Performance

Latest quarter financial snapshot was unavailable due to an error, so there is no reliable quarterly revenue or earnings detail to assess growth trends. Based on the provided data, there is not enough financial evidence here to support a strong fundamental buy decision for a long-term beginner investor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible recent Wall Street upgrade/downgrade trend to confirm bullish or bearish conviction. Wall Street pros and cons view is therefore mixed: the chart and congress buying are positives, but the lack of analyst support, lack of news catalysts, and bearish options flow argue against an aggressive buy.

Wall Street analysts forecast PCVX stock price to rise
6 Analyst Rating
Wall Street analysts forecast PCVX stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 60.670
sliders
Low
50
Averages
104.8
High
163
Current: 60.670
sliders
Low
50
Averages
104.8
High
163
TD Cowen
Tara Bancroft
Buy
upgrade
$50 -> $75
AI Analysis
2026-02-25
Reason
TD Cowen
Tara Bancroft
Price Target
$50 -> $75
AI Analysis
2026-02-25
upgrade
Buy
Reason
TD Cowen analyst Tara Bancroft raised the firm's price target on Vaxcyte to $75 from $50 and keeps a Buy rating on the shares. The firm said Vaxcyte enters 2026 with a largely de-risked path for VAX-31, supported by differentiated Phase II data and a comprehensive Phase III OPUS program targeting BLA filing in 2027.
Goldman Sachs
Neutral
maintain
$38 -> $67
2026-02-25
Reason
Goldman Sachs
Price Target
$38 -> $67
2026-02-25
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Vaxcyte to $67 from $38 and keeps a Neutral rating on the shares. Since coverage initiation, shares have risen steadily due to clinical progress on VAX-31, a slower-than-expected competitive landscape, and stable policy around the 4-dose infant schedule, contributing to year-to-date outperformance, the analyst tells investors in a research note. Upcoming VAX-31 Phase 3 adult data, Phase 2 pediatric readouts, and competitive developments viewed as key de-risking catalysts, the firm adds.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PCVX
Unlock Now

People Also Watch